Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

Published:2021-02-24 Issue:2 Volume:4 Page:e210037
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Su Dan¹,Wu Bin²,Shi Lizheng³

Affiliation:

1. Department of Pharmacy, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China

2. Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, Shanghai Jiaotong University School of Medicine, Shanghai, China

3. Department of Global Health Management and Policy, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2776749/su_2021_oi_210004_1613516814.09594.pdf

Reference27 articles.

1. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.;GBD 2017 DALYs and HALE Collaborators;Lancet,2018

2. Hepatocellular carcinoma.;Forner;Lancet,2018

3. Efficacy of treatment regimens for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials.;Chen;Medicine (Baltimore),2019

4. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.;Kudo;Lancet,2018

5. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.;Finn;N Engl J Med,2020

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China;International Journal of Clinical Pharmacy;2024-09-14

2. Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States;Frontiers in Immunology;2024-09-13

3. The current status and future of targeted-immune combination for hepatocellular carcinoma;Frontiers in Immunology;2024-08-05

4. Impact of Type of Lenvatinib Resistance on Prognosis and Second-Line Regimen in Patients with Virus-Associated HCC;Journal of Hepatocellular Carcinoma;2024-08

5. Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review;Health Economics Review;2024-07-05